Biotechnology News and Research

RSS

Israeli researchers establish novel optogenetic method for cardiac pacing and resynchronization

Israeli researchers have successfully established a new approach for pacing the heart and synchronizing its mechanical activity without the use of a conventional electrical pacemaker. This novel biologic strategy employs light-sensitive genes that can be injected into the heart and then activated by flashes of blue light.

23 Jun 2015

3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the ex-China global rights to Apexigen's anti-TNF monoclonal antibody ("mAb") technology. 3SBio previously acquired the China rights from Apexigen in 2006.

23 Jun 2015

Wockhardt obtains final approval from FDA for marketing 5mg/ 5ml of Oxycodone HCl liquid

Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 5mg/ 5ml of Oxycodone HCl liquid which is used in treatment of moderate to severe acute and chronic pain. Wockhardt is launching the product soon and will be amongst the few generic versions of this product in the market.

22 Jun 2015

VG Life Sciences receives U.S. patent for combination cancer therapy

VG Life Sciences, Inc., a biotechnology company developing therapies for cancer, autoimmune and infectious diseases, announced that the U.S. Patent and Trademark Office will issue Patent No. 9073985 covering VGLS' combination therapy for treating drug-resistant cancer by combining an autophagy inhibitor with a chemotherapy drug.

22 Jun 2015

Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

Benitec Biopharma is pleased to announce the launch of a new exploratory cellular therapy program including exosome-based delivery utilising the Company's proprietary ddRNAi technology. Entry into these areas have been facilitated by the commencement of a collaboration with UK-based stem cell therapeutics company, ReNeuron.

22 Jun 2015

MedDay announces additional positive results from MD1003 Phase III trial in patients with progressive MS

MedDay, a biotechnology company focused on the treatment of nervous system disorders, reports additional positive data from its pivotal Phase III clinical trial, MS-SPI, with MD1003, a highly-concentrated pharmaceutical grade biotin, in patients with Progressive Multiple Sclerosis.

19 Jun 2015

Florida Institute finalizes funding agreement with TransGenex Nanobiotech

The Florida Institute for the Commercialization of Public Research announced today that it has finalized a funding agreement with TransGenex Nanobiotech, Inc., a company that is developing nano-scale technologies for novel, cost-effective diagnostic and therapeutic agents against cancers and other inflammatory diseases.

19 Jun 2015

$Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC$

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Amgen today announced that a Phase 3 study evaluating Vectibix (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) compared to those patients treated with BSC alone.

19 Jun 2015

PAREXEL expands Perceptive MyTrials Data-Driven Monitoring solution

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today launched next generation risk-based monitoring capabilities, expanding its Perceptive MyTrials Data-Driven Monitoring (DDM) solution.

From Parexel 18 Jun 2015

Hitachi High-Technologies, QIAGEN form new strategic partnership to advance molecular testing

Hitachi High-Technologies Corporation and QIAGEN N.V. have entered into a long-term strategic collaboration involving initiatives to deliver important advances in molecular testing.

From QIAGEN Manchester Limited 18 Jun 2015

Findings could lead to treatments for chronic pain caused by nerve damage

Non-narcotic treatments for chronic pain that work well in people, not just mice, are sorely needed. Drawing from human pain genetics, an international team led by Boston Children's Hospital demonstrates a way to break the cycle of pain hypersensitivity without the development of addiction, tolerance or side effects.

18 Jun 2015

Accurexa seeks FDA clearance to market BranchPoint device

Accurexa Inc., a biotechnology company focused on developing and commercializing novel neurological therapies, announced on Monday that it has filed a submission with the U.S. FDA for 510(k) clearance to market its BranchPoint device.

17 Jun 2015

Allergan agrees to acquire KYTHERA Biopharmaceuticals for $2.1 billion

Allergan plc, a leading global pharmaceutical company, and KYTHERA Biopharmaceuticals, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market, today announced that they have entered into a definitive agreement under which Allergan has agreed to acquire KYTHERA in a cash and equity transaction valued at $75 per KYTHERA share, or approximately $2.1 billion.

17 Jun 2015

New open access journal to deliver case reports on all aspects of pancreatic cancer

Case Reports in Pancreatic Cancer, a new peer-reviewed, open access journal from Mary Ann Liebert, Inc., publishers, will deliver authoritative case reports on all aspects of pancreatic cancer diagnosis, management, treatment, and outcomes.

17 Jun 2015

Breastfeeding Medicine editorial examines risks associated with Internet-purchased breast milk

The practice of breast milk sharing among mothers has evolved into an Internet-based marketplace in which this valuable commodity is being bought and sold not only to feed babies, but as a "natural superfood" for body builders and athletes.

17 Jun 2015

New DARPA grant supports Wyss Institute project that aims to fight gastrointestinal illness

For decades, American travelers to international destinations have been plagued by acute gastrointestinal illnesses that can arise from travel to other countries. The Center for Disease Control warns that depending on the destination, between 30 to 70 percent of travelers can expect to experience gastrointestinal distress from ingesting foreign or pathogenic bacteria that can be present in poorly sanitized water or food.

17 Jun 2015

CytomX closes $70 million Series D financing round

CytomX, a biotechnology company developing Probody™ therapeutics for the treatment of cancer, today announced the closing of a $70 million Series D financing round. The financing was led by Fidelity Management & Research Company with participation from Casdin Capital, Cormorant Asset Management, Deerfield Management, Perceptive Advisors, Redmile Group, Tekla Healthcare Investors and Tekla Life Sciences Investors, Venrock Healthcare Capital Partners, Wellington Management Company and additional undisclosed investors.

17 Jun 2015

CQDM, OCE grant $1.5M to speed up drug discovery and development in Quebec-Ontario Life Sciences Corridor

CQDM and Ontario Centres of Excellence will fund five highly innovative and unconventional game-changing research and development projects to accelerate drug discovery in the Quebec-Ontario Life Sciences Corridor. Partners are granting $1.5M to Quebec-based and, for the first time, Ontario-based researchers thanks to the partnership with OCE through CQDM's 2014 Explore Program, one of CQDM's flagship programs focusing on early concept validation of cutting-edge technologies that address the most crucial needs in drug discovery and development.

17 Jun 2015

Scientists identify two new key players involved in development of prostate cancer

Understanding how a normal healthy cell turns into a cancerous one is our best bet yet for beating the disease. It will help better diagnose the cancer type, and enable the development of more effective, and less toxic therapies. But cells have evolved all sorts of sophisticated ways to become cancerous, and identifying the molecules involved and how they function in each type of cancer is a major undertaking.

16 Jun 2015

Genticel’s GTL001 phase 1 clinical study of HPV therapeutic vaccine granted FDA clearance

Genticel, a French biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the US Food and Drug Administration (FDA) has cleared Genticel’s Investigational New Drug application to conduct in the US a phase 1 clinical study of GTL001 in patients infected with HPV 16 and/or 18, the two HPV types responsible for 70% of cervical cancer cases.

16 Jun 2015

Biotechnology News and Research

Israeli researchers establish novel optogenetic method for cardiac pacing and resynchronization

3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

Wockhardt obtains final approval from FDA for marketing 5mg/ 5ml of Oxycodone HCl liquid

VG Life Sciences receives U.S. patent for combination cancer therapy

Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

MedDay announces additional positive results from MD1003 Phase III trial in patients with progressive MS

Florida Institute finalizes funding agreement with TransGenex Nanobiotech

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

PAREXEL expands Perceptive MyTrials Data-Driven Monitoring solution

Hitachi High-Technologies, QIAGEN form new strategic partnership to advance molecular testing

Findings could lead to treatments for chronic pain caused by nerve damage

Accurexa seeks FDA clearance to market BranchPoint device

Allergan agrees to acquire KYTHERA Biopharmaceuticals for $2.1 billion

New open access journal to deliver case reports on all aspects of pancreatic cancer

Breastfeeding Medicine editorial examines risks associated with Internet-purchased breast milk

New DARPA grant supports Wyss Institute project that aims to fight gastrointestinal illness

CytomX closes $70 million Series D financing round

CQDM, OCE grant $1.5M to speed up drug discovery and development in Quebec-Ontario Life Sciences Corridor

Scientists identify two new key players involved in development of prostate cancer

Genticel’s GTL001 phase 1 clinical study of HPV therapeutic vaccine granted FDA clearance

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News